If you think about the rise of specialty drugs as a Category 5 hurricane, and the growth of gene therapies as an undersea earthquake, you can see the rising tsunami of drug spend looking to sweep...

The SIU promotes safety to prevent fraud, waste and abuse schemes

New Biosimilars First Generic Drug Launches Oct. 25, 2024 - sulopenem etzadroxil and probenecid (Orlynvah) The FDA has approved Iterum’s Orlynvah for the treatment of uncomplicated urinary tract...

Recent webinar featuring Prime Therapeutics experts shares some of the latest breakthrough therapies — including ADCs, BiTes and CAR-T treatments — and regulatory changes and market shifts that are...